PT - JOURNAL ARTICLE AU - Igor Vidal AU - Qizhi Zheng AU - Jessica L. Hicks AU - Jiayu Chen AU - Elizabeth A. Platz AU - Bruce J. Trock AU - Ibrahim Kulac AU - Javier Baena-Del Valle AU - Karen S. Sfanos AU - Sarah Ernst AU - Tracy Jones AU - Stephanie Glavaris AU - William G. Nelson AU - Srinivasan Yegnasubramanian AU - Angelo M. De Marzo TI - GSTP1 positive prostatic adenocarcinomas are more common in Black than White men in the United States AID - 10.1101/2020.08.28.20183954 DP - 2020 Jan 01 TA - medRxiv PG - 2020.08.28.20183954 4099 - http://medrxiv.org/content/early/2020/09/01/2020.08.28.20183954.short 4100 - http://medrxiv.org/content/early/2020/09/01/2020.08.28.20183954.full AB - GSTP1 is a member of the Glutathione-S-transferase (GSTS) family silenced by CpG island DNA hypermethylation in 90-95% of prostate cancers. However, prostate cancers expressing GSTP1 have not been well characterized. We used immunohistochemistry against GSTP1 to examine 1673 primary prostatic adenocarcinomas on TMAs with redundant sampling from the index tumor from prostatectomies. GSTP1 protein was positive in at least one TMA core in 7.7% of cases and in all TMA cores in 4.4% of cases. The percentage of adenocarcinomas from Black patients who had any GSTP1 positive TMA cores was 14.9%, which was 2.5 times higher than the percentage from White patients (5.9%; P < 0.001). Further, the percentages of tumors from Black patients who had all TMA spots positive for GSTP1 (9.5%) was 3-fold higher than the percentage from White patients (3.2%; P<0.001). The increased percentage of GSTP1 positive cases in Black men was present only in ERG positive cases. By in situ hybridization, GSTP1 mRNA expression was concordant with protein staining, supporting the lack of silencing of at least some GSTP1 alleles in GSTPI-positive tumor cells. This is the first report revealing that the GSTPI-positive prostate cancer subset is substantially over-represented among prostate cancers from Black compared to White men. This observation should prompt additional studies to determine whether GSTP1 positive cases represent a distinct molecular subtype of prostate cancer and whether GSTP1 expression could provide a biological underpinning for the observed disparate outcomes for Black men.Competing Interest StatementpendingFunding StatementSupported by U.S. NIH/NCI SPORE in Prostate Cancer: P50CA58236, and the U.S. NIH/NCI U01 CA196390 for the Molecular and Cellular Characterization of Screen Detected Lesions (MCL), the U.S. Department of Defense Prostate Cancer Research Program (PCRP): W81XWH-18-2-0015. The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Oncology Tissue Services Laboratory supported by NIH/NCI grant P30 CA006973.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Johns Hopkins University School of MedicineAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesnot applicable